

DIAGNOSTICS AND THERAPEUTICS FOR LUNG CANCER: GLOBAL MARKETS



PHM174A
May 2015

Vijay Laxmi
Project Analyst

ISBN: 1-62296-091-2



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY AND OBJECTIVES	2
TITLE DESCRIPTION	2
SCOPE OF THE REPORT	2
MARKET STRUCTURE	3
INTENDED AUDIENCE	3
RESEARCH METHODOLOGY	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
SCOPE OF LUNG CANCER	6
LUNG CANCER EPIDEMIOLOGY TRENDS	6
CURRENT DIAGNOSTICS AND THERAPEUTIC TREATMENTS OF LUNG CANCER	7
UNMET MARKET NEEDS	7
RESEARCH AND DEVELOPMENT (R&D) TRENDS	7
PIPELINE ANALYSIS	8
<i>SUMMARY TABLE GLOBAL MARKET FOR LUNG CANCER, THROUGH 2019 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR LUNG CANCER, 2013-2019 (\$ MILLIONS)</i>	8
CHAPTER 3 MARKET OVERVIEW	11
MARKET DEFINITION AND GLOBAL CANCER STATISTICS	11
CANCER DIAGNOSIS AND THERAPY MANAGEMENT	11
LUNG CANCER OVERVIEW AND STATISTICS	12
TYPES AND STAGES OF LUNG CANCER	12
NON-SMALL CELL LUNG CANCER (NSCLC)	13
Staging of NSCLC	13
SMALL CELL LUNG CANCER (SCLC)	14
Staging of SCLC	14
LUNG CANCER DIAGNOSIS AND THERAPY MANAGEMENT	14
MARKET ISSUES RELATED TO LUNG CANCER	16
HIGH DRUG COST	16
DRUG APPROVAL TIMELINE	16
DRUG RESISTANCE TO CANCER DRUGS	17
NOT ENOUGH PATIENTS IN CLINICAL TRIALS	17
FEDERAL EXPENDITURE	18
<i>FIGURE 1 CANCER RESEARCH FUNDING, 2012 (DOLLARS PER LIFE COST)</i>	18
<i>FIGURE 2 FEDERAL FUNDING BY CANCER SITE, 2012 (\$ MILLIONS)</i>	18
<i>FIGURE 3 FIVE-YEAR SURVIVAL RATES BY YEAR OF DIAGNOSIS (%)</i>	19
RECESSION IN THE GLOBAL ECONOMY	20
INNOVATIONS IN METHODS OF DIAGNOSTICS AND THERAPEUTICS OF LUNG CANCER	20
LUNG CANCER MARKET ANALYSIS	21

TOPIC	PAGE NO.
NICE LIMITS THE USE OF ROCHE'S TARCEVA IN LUNG CANCER	21
ELI LILLY'S ALMITA LOSES PATENT WAR IN THE U.K.	21
FOCUS IS ON INCREASING DIFFERENTIATION BETWEEN THE THREE MAIN NSCLC SUBTYPES	22
DRUG RESISTANCE TO THERAPIES	22
USE OF LOW-DOSE COMPUTED TOMOGRAPHY TO DETECT EARLY-STAGE LUNG CANCER	22
LUNG CANCER IN NON-SMOKERS	22
ASTRAZENECA'S MEDI4736, A VERY VIABLE DRUG FOR TREATING LUNG CANCER	22
LUNG CANCER MARKET STRATEGIES	23
MARKET SHARE OF KEY COMPANIES	24
<i>FIGURE 4 MARKET SHARE OF KEY COMPANIES IN THE LUNG CANCER DIAGNOSTICS MARKET, 2014 (%)</i>	24
GLOBAL MARKET FOR LUNG CANCER	25
<i>TABLE 1 GLOBAL MARKET FOR LUNG CANCER BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	25
REGULATIONS	26
UNITED STATES	26
<i>FIGURE 5 DRUG DISCOVERY AND DEVELOPMENT TIMELINE</i>	27
CANADA	28
EUROPE	29
Nationalized Procedure	29
Mutual Recognition Procedure (MRP)	29
<i>FIGURE 6 MUTUAL RECOGNITION PROCEDURE</i>	30
Decentralized Procedure	30
<i>FIGURE 7 DECENTRALIZED PROCEDURE</i>	31
Centralized Procedure	31
INDIA	32
<i>FIGURE 8 DRUG APPROVAL PROCESS IN INDIA</i>	32
CHINA	33
Step 1: Application for Approval of Clinical Study (Clinical Trial or Bio-Efficacy Study)	34
<i>FIGURE 9 DRUG APPROVAL PROCESS IN CHINA</i>	34
Step 2: Conducting Clinical Studies	35
<i>FIGURE 10 PROCEDURE FOR CLINICAL STUDIES</i>	35
Step 3: Final Approval for Drug Registration (After Clinical Studies)	36
<i>FIGURE 11 FINAL APPROVAL FOR DRUG REGISTRATION</i>	36
AFRICA	36
GOVERNMENT-SUPPORTED PROGRAMS	38
UNITED STATES	38
CANADA	39
EUROPE	40
INDIA	41
CHINA	42
AFRICA	42
COMMERCIALIZING NEXT-GENERATION CANCER TESTS	43
<i>FIGURE 12 PENETRANCE BREAKDOWN OF NEXT-GENERATION SEQUENCING TESTS, 2013 (%)</i>	44

TOPIC	PAGE NO.
CURRENT MARKET SCENARIO	45
REGULATORY REQUIREMENTS OF CANCER TESTS	46
REIMBURSEMENT CODING IN THE U.S.	48
ICD	48
GENE PATENTS AND TEST COMMERCIALIZATION	49
GENE PATENTING	50
<i>FIGURE 13 BREAKDOWN OF GENETIC TESTS MARKET, 2013 (%)</i>	52
MAJOR COMPANIES IN THE GENETICS SERVICES MARKET	53
IMPACT OF COMPANION TEST DEVELOPMENT	54
CONCLUSIONS AND STRATEGIC IMPLICATIONS	55
UNMET MARKET NEEDS	55
PIPELINE ANALYSIS	56
CHAPTER 4 LUNG CANCER DIAGNOSTICS MARKET	60
OVERVIEW	60
<i>TABLE 2 GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	60
<i>TABLE 3 GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY DIAGNOSTIC TEST, THROUGH 2019 (\$ MILLIONS)</i>	61
RESEARCH AND DEVELOPMENT	61
INNOVATIONS	62
TRENDS	63
REGULATIONS	63
COMPETITIVE LANDSCAPE	63
HISTOLOGY/CYTOLOGY	63
MARKET OVERVIEW	63
<i>TABLE 4 GLOBAL MARKET FOR HISTOLOGY/CYTOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	64
COMPETITIVE LANDSCAPE	64
IMMUNOASSAYS	66
MARKET OVERVIEW	66
<i>TABLE 5 GLOBAL MARKET FOR IMMUNOASSAYS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	66
COMPETITIVE LANDSCAPE	67
FLOW CYTOMETRY	68
MARKET OVERVIEW	68
<i>TABLE 6 GLOBAL MARKET FOR FLOW CYTOMETRY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	68
COMPETITIVE LANDSCAPE	69
RAPID TESTS	70
MARKET OVERVIEW	70
<i>TABLE 7 GLOBAL MARKET FOR RAPID TESTS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	70
COMPETITIVE LANDSCAPE	70
<i>TABLE 8 LIST OF ALERE TEST PRODUCTS</i>	71
MOLECULAR ASSAYS	72
MARKET OVERVIEW	72
<i>TABLE 9 GLOBAL MARKET FOR MOLECULAR ASSAYS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	72

TOPIC	PAGE NO.
COMPETITIVE LANDSCAPE	73
TABLE 10 MYRIAD GENETICS TESTS	74
TISSUE ARRAYS	74
MARKET OVERVIEW	74
TABLE 11 GLOBAL MARKET FOR TISSUE ARRAYS BY REGION, THROUGH 2019 (\$ MILLIONS)	74
COMPETITIVE LANDSCAPE	75
CIRCULATING TUMOR CELLS	76
MARKET OVERVIEW	76
TABLE 12 GLOBAL MARKET FOR CIRCULATING TUMOR CELLS BY REGION, THROUGH 2019 (\$ MILLIONS)	77
COMPETITIVE LANDSCAPE	77
PHARMACODIAGNOSTICS, MOLECULAR	78
MARKET OVERVIEW	78
TABLE 13 GLOBAL MARKET FOR PHARMACODIAGNOSTICS, MOLECULAR BY REGION, THROUGH 2019 (\$ MILLIONS)	79
COMPETITIVE LANDSCAPE	79
BIOMARKERS	80
MARKET OVERVIEW	80
TABLE 14 GLOBAL MARKET FOR BIOMARKERS BY REGION, THROUGH 2019 (\$ MILLIONS)	80
COMPETITIVE LANDSCAPE	81
OTHER DIAGNOSTICS METHODS	81
DIGITAL PCR	81
Market Overview	81
Competitive Landscape	82
MASS SPECTROMETRY	83
Market Overview	83
Competitive Landscape	83
CHROMOSOME ANALYSIS	86
Market Overview	86
Competitive Landscape	86
NEXT-GENERATION SEQUENCING	86
Market Overview	86
Competitive Landscape	87
SAMPLE PREPARATION AND SYSTEM AUTOMATION	88
Market Overview	88
Competitive Landscape	89
ROLE OF IN VIVO CELLULAR AND MOLECULAR IMAGING	90
Market Overview	90
Competitive Landscape	91
CHAPTER 5 LUNG CANCER THERAPEUTICS MARKET	94
OVERVIEW	94
TABLE 15 GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY REGION, THROUGH 2019 (\$ MILLIONS)	94
TABLE 16 GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY THERAPY TYPE, THROUGH 2019 (\$ MILLIONS)	94
FIGURE 14 PREVALENCE OF LUNG CANCER BY TYPE, 2014 (%)	95

TOPIC	PAGE NO.
CHEMOTHERAPY	95
<i>TABLE 17 GLOBAL MARKET FOR LUNG CANCER CHEMOTHERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	96
DIFFERENT CONDITIONS IN CHEMOTHERAPY	96
<i>FIGURE 15 BREAKDOWN OF LUNG CANCER DIAGNOSIS BY STAGE, 2004-2010 (%)</i>	96
Chemotherapy after Surgery	97
Chemotherapy and Radiotherapy	97
Chemotherapy for Locally Advanced NSCLC or Cancer that Has Spread	97
CHEMOTHERAPY DRUGS	97
LOW-COST DESTINATION FOR CHEMOTHERAPY	98
<i>TABLE 18 COST COMPARISON OF LUNG CANCER TREATMENTS IN THE U.S. AND INDIA (\$)</i>	98
INCREASING NUMBER OF LUNG CANCER PATIENTS IN THE U.S.	98
<i>FIGURE 16 NUMBER OF CANCER CASES IN THE U.S. BY TYPE, 2014 (NUMBER OF CASES)</i>	98
RADIOTHERAPY	99
<i>TABLE 19 RADIATION THERAPY AND COST IN THE U.S., 2014 (\$)</i>	100
LINEAR ACCELERATOR RADIOTHERAPY MACHINES	100
PROTON THERAPY	101
PARTICLE THERAPY	101
<i>FIGURE 17 ADVANTAGES AND DISADVANTAGES OF PARTICLE THERAPY</i>	102
RADIOTHERAPY MACHINES MUST NOT BE OUTDATED	102
RADIOTHERAPY TO INCREASE GLOBALLY	102
<i>TABLE 20 GLOBAL MARKET FOR LUNG CANCER RADIOTHERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	103
SURGERY	103
<i>TABLE 21 GLOBAL MARKET FOR LUNG CANCER SURGERY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	103
TYPES OF SURGERY	104
<i>FIGURE 18 GLOBAL MARKET SHARE FOR LUNG CANCER SURGERY BY TYPE, 2014 (%)</i>	104
Thoracotomy	105
Robotic Surgery	105
Video-Assisted Thoracoscopic Surgery (VATS)	105
GEOGRAPHICAL ANALYSIS OF LUNG CANCER SURGERIES	105
The U.S.	106
Europe	106
The U.K.	106
APAC	107
CHAPTER 6 COMPETITIVE LANDSCAPE	109
<i>FIGURE 19 TOP STRATEGIC ACTIVITIES OF KEY COMPANIES, 2011-NOVEMBER 2014 (NUMBER)</i>	109
<i>TABLE 22 PRODUCT LAUNCHES AND APPROVALS IN THE LUNG CANCER MARKET, 2011 TO 2014</i>	110
<i>TABLE 23 AGREEMENTS AND EXPANSIONS IN LUNG CANCER MARKET, 2011 TO 2014</i>	119
<i>TABLE 24 MERGERS AND ACQUISITIONS AND OTHER STRATEGIES IN THE LUNG CANCER MARKET, 2011 TO 2014</i>	125

TOPIC	PAGE NO.
CHAPTER 7 COMPANY PROFILES	130
ABBOTT LABORATORIES	130
<i>TABLE 25 ABBOTT'S PRODUCT PORTFOLIO</i>	130
<i>TABLE 26 ABBOTT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	130
ACCURAY INC.	131
<i>TABLE 27 ACCURAY'S PRODUCT PORTFOLIO</i>	132
<i>TABLE 28 ACCURAY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	132
AGILENT TECHNOLOGIES	134
<i>TABLE 29 AGILENT'S PRODUCT PORTFOLIO</i>	134
<i>TABLE 30 AGILENT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	135
ARRAY BIOPHARMA	137
<i>TABLE 31 ARRAY BIOPHARMA'S PRODUCT PORTFOLIO</i>	137
<i>TABLE 32 ARRAY BIOPHARMA'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	138
ASURAGEN, INC.	138
<i>TABLE 33 ASURAGEN'S PRODUCT PORTFOLIO</i>	139
<i>TABLE 34 ASURAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	139
BECKMAN COULTER, INC.	139
<i>TABLE 35 BECKMAN COULTERS PRODUCT PORTFOLIO</i>	140
BECTON DICKINSON	140
<i>TABLE 36 BECTON DICKINSON'S PRODUCT PORTFOLIO</i>	140
<i>TABLE 37 BECTON DICKINSON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	141
BIOMERIEUX	142
<i>TABLE 38 BIOMERIEUX'S PRODUCT PORTFOLIO</i>	142
<i>TABLE 39 BIOMERIEUX'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	143
BIO-RAD LABORATORIES	143
<i>TABLE 40 BIO-RAD'S PRODUCT PORTFOLIO</i>	144
<i>TABLE 41 BIO-RAD'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	144
BOEHRINGER INGELHEIM	146
<i>TABLE 42 BOEHRINGER INGELHEIM'S PRODUCT PORTFOLIO</i>	147
<i>TABLE 43 BOEHRINGER INGELHEIM'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	147
BRUKER CORPORATION	148
<i>TABLE 44 BRUKER'S PRODUCT PORTFOLIO</i>	149
<i>TABLE 45 BRUKER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	149
COVIDIEN PLC	149
<i>TABLE 46 COVIDIEN'S PRODUCT PORTFOLIO</i>	150
<i>TABLE 47 COVIDIEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	150
DAKO DENMARK A/S	152
<i>TABLE 48 DAKO'S PRODUCT PORTFOLIO</i>	152
<i>TABLE 49 DAKO'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	152
DANAHER CORPORATION	153
<i>TABLE 50 DANAHER'S PRODUCT PORTFOLIO</i>	153
ELI LILLY	153
<i>TABLE 51 ELI LILLY'S PRODUCT PORTFOLIO</i>	154

TOPIC	PAGE NO.
<i>TABLE 52 ELI LILLY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	155
ETHICON ENDO-SURGERY INC.	155
<i>TABLE 53 ETHICON'S PRODUCT PORTFOLIO</i>	156
<i>TABLE 54 ETHICON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	156
HOLOGIC	157
<i>TABLE 55 HOLOGIC'S PRODUCT PORTFOLIO</i>	158
<i>TABLE 56 HOLOGIC'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	158
MERCK MILLIPORE	159
<i>TABLE 57 MERCK MILLIPORE PRODUCT PORTFOLIO</i>	159
<i>TABLE 58 MERCK MILLIPORE RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	159
OLYMPUS CORP.	160
<i>TABLE 59 OLYMPUS' PRODUCT PORTFOLIO</i>	160
PFIZER	160
<i>TABLE 60 PFIZER'S PRODUCT PORTFOLIO</i>	161
<i>TABLE 61 PFIZER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	161
QIAGEN	162
<i>TABLE 62 QIAGEN'S PRODUCT PORTFOLIO</i>	163
<i>TABLE 63 QIAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	163
RAYBIOTECH	165
<i>TABLE 64 RAYBIOTECH'S PRODUCT PORTFOLIO</i>	166
<i>TABLE 65 RAYBIOTECH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	166
ROCHE DIAGNOSTICS	166
<i>TABLE 66 ROCHE DIAGNOSTICS' PRODUCT PORTFOLIO</i>	167
<i>TABLE 67 ROCHE DIAGNOSTICS' RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	167
SIEMENS HEALTHCARE	169
<i>TABLE 68 SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO</i>	169
<i>TABLE 69 SIEMENS HEALTHCARE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	170
SIGMA ALDRICH	170
<i>TABLE 70 SIGMA-ALDRICH'S PRODUCT PORTFOLIO</i>	171
<i>TABLE 71 SIGMA-ALDRICH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	171
THERMO FISHER SCIENTIFIC	171
<i>TABLE 72 THERMO FISHER'S PRODUCT PORTFOLIO</i>	172
<i>TABLE 73 THERMO FISHER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	172
TRANSGENE SA	172
<i>TABLE 74 TRANSGENE'S PRODUCT PORTFOLIO</i>	173
<i>TABLE 75 TRANSGENE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014</i>	173
TRINITY BIOTECH	174
<i>TABLE 76 TRINITY'S PRODUCT PORTFOLIO</i>	174
CHAPTER 8 PATENT ANALYSIS	176
<i>FIGURE 20 NUMBER OF PATENTS BY REGION, 2011 TO NOVEMBER 2014 (NUMBER)</i>	176
LIST OF PATENTS	177
UNITED STATES	177
<i>TABLE 77 U.S. PATENTS, 2011 TO NOVEMBER 2014</i>	177

TOPIC	PAGE NO.
EUROPE	180
<i>TABLE 78 EUROPE'S PATENTS, 2011 TO NOVEMBER 2014</i>	180
JAPAN	185
<i>TABLE 79 JAPAN'S PATENTS, 2010 TO NOVEMBER 2014</i>	185

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR LUNG CANCER, THROUGH 2019 (\$ MILLIONS)	8
TABLE 1 GLOBAL MARKET FOR LUNG CANCER BY TYPE, THROUGH 2019 (\$ MILLIONS)	25
TABLE 2 GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY REGION, THROUGH 2019 (\$ MILLIONS)	60
TABLE 3 GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY DIAGNOSTIC TEST, THROUGH 2019 (\$ MILLIONS)	61
TABLE 4 GLOBAL MARKET FOR HISTOLOGY/CYTOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)	64
TABLE 5 GLOBAL MARKET FOR IMMUNOASSAYS BY REGION, THROUGH 2019 (\$ MILLIONS)	66
TABLE 6 GLOBAL MARKET FOR FLOW CYTOMETRY BY REGION, THROUGH 2019 (\$ MILLIONS)	68
TABLE 7 GLOBAL MARKET FOR RAPID TESTS BY REGION, THROUGH 2019 (\$ MILLIONS)	70
TABLE 8 LIST OF ALERE TEST PRODUCTS	71
TABLE 9 GLOBAL MARKET FOR MOLECULAR ASSAYS BY REGION, THROUGH 2019 (\$ MILLIONS)	72
TABLE 10 MYRIAD GENETICS TESTS	74
TABLE 11 GLOBAL MARKET FOR TISSUE ARRAYS BY REGION, THROUGH 2019 (\$ MILLIONS)	74
TABLE 12 GLOBAL MARKET FOR CIRCULATING TUMOR CELLS BY REGION, THROUGH 2019 (\$ MILLIONS)	77
TABLE 13 GLOBAL MARKET FOR PHARMACODIAGNOSTICS, MOLECULAR BY REGION, THROUGH 2019 (\$ MILLIONS)	79
TABLE 14 GLOBAL MARKET FOR BIOMARKERS BY REGION, THROUGH 2019 (\$ MILLIONS)	80
TABLE 15 GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY REGION, THROUGH 2019 (\$ MILLIONS)	94
TABLE 16 GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY THERAPY TYPE, THROUGH 2019 (\$ MILLIONS)	94
TABLE 17 GLOBAL MARKET FOR LUNG CANCER CHEMOTHERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)	96
TABLE 18 COST COMPARISON OF LUNG CANCER TREATMENTS IN THE U.S. AND INDIA (\$)	98
TABLE 19 RADIATION THERAPY AND COST IN THE U.S., 2014 (\$)	100
TABLE 20 GLOBAL MARKET FOR LUNG CANCER RADIOTHERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)	103
TABLE 21 GLOBAL MARKET FOR LUNG CANCER SURGERY BY REGION, THROUGH 2019 (\$ MILLIONS)	103
TABLE 22 PRODUCT LAUNCHES AND APPROVALS IN THE LUNG CANCER MARKET, 2011 TO 2014	110
TABLE 23 AGREEMENTS AND EXPANSIONS IN LUNG CANCER MARKET, 2011 TO 2014	119
TABLE 24 MERGERS AND ACQUISITIONS AND OTHER STRATEGIES IN THE LUNG CANCER MARKET, 2011 TO 2014	125
TABLE 25 ABBOTT'S PRODUCT PORTFOLIO	130
TABLE 26 ABBOTT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	130
TABLE 27 ACCURAY'S PRODUCT PORTFOLIO	132
TABLE 28 ACCURAY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	132
TABLE 29 AGILENT'S PRODUCT PORTFOLIO	134
TABLE 30 AGILENT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	135

TABLE HEADING	PAGE NO.
TABLE 31 ARRAY BIOPHARMA'S PRODUCT PORTFOLIO	137
TABLE 32 ARRAY BIOPHARMA'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	138
TABLE 33 ASURAGEN'S PRODUCT PORTFOLIO	139
TABLE 34 ASURAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	139
TABLE 35 BECKMAN COULTERS PRODUCT PORTFOLIO	140
TABLE 36 BECTON DICKINSON'S PRODUCT PORTFOLIO	140
TABLE 37 BECTON DICKINSON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	141
TABLE 38 BIOMERIEUX'S PRODUCT PORTFOLIO	142
TABLE 39 BIOMERIEUX'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	143
TABLE 40 BIO-RAD'S PRODUCT PORTFOLIO	144
TABLE 41 BIO-RAD'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	144
TABLE 42 BOEHRINGER INGELHEIM'S PRODUCT PORTFOLIO	147
TABLE 43 BOEHRINGER INGELHEIM'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	147
TABLE 44 BRUKER'S PRODUCT PORTFOLIO	149
TABLE 45 BRUKER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	149
TABLE 46 COVIDIEN'S PRODUCT PORTFOLIO	150
TABLE 47 COVIDIEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	150
TABLE 48 DAKO'S PRODUCT PORTFOLIO	152
TABLE 49 DAKO'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	152
TABLE 50 DANAHER'S PRODUCT PORTFOLIO	153
TABLE 51 ELI LILLY'S PRODUCT PORTFOLIO	154
TABLE 52 ELI LILLY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	155
TABLE 53 ETHICON'S PRODUCT PORTFOLIO	156
TABLE 54 ETHICON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	156
TABLE 55 HOLOGIC'S PRODUCT PORTFOLIO	158
TABLE 56 HOLOGIC'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	158
TABLE 57 MERCK MILLIPORE PRODUCT PORTFOLIO	159
TABLE 58 MERCK MILLIPORE RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	159
TABLE 59 OLYMPUS' PRODUCT PORTFOLIO	160
TABLE 60 PFIZER'S PRODUCT PORTFOLIO	161
TABLE 61 PFIZER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	161
TABLE 62 QIAGEN'S PRODUCT PORTFOLIO	163
TABLE 63 QIAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	163
TABLE 64 RAYBIOTECH'S PRODUCT PORTFOLIO	166
TABLE 65 RAYBIOTECH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	166
TABLE 66 ROCHE DIAGNOSTICS' PRODUCT PORTFOLIO	167
TABLE 67 ROCHE DIAGNOSTICS' RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	167
TABLE 68 SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO	169
TABLE 69 SIEMENS HEALTHCARE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	170
TABLE 70 SIGMA-ALDRICH'S PRODUCT PORTFOLIO	171
TABLE 71 SIGMA-ALDRICH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	171
TABLE 72 THERMO FISHER'S PRODUCT PORTFOLIO	172

TABLE HEADING	PAGE NO.
TABLE 73 THERMO FISHER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	172
TABLE 74 TRANSGENE'S PRODUCT PORTFOLIO	173
TABLE 75 TRANSGENE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014	173
TABLE 76 TRINITY'S PRODUCT PORTFOLIO	174
TABLE 77 U.S. PATENTS, 2011 TO NOVEMBER 2014	177
TABLE 78 EUROPE'S PATENTS, 2011 TO NOVEMBER 2014	180
TABLE 79 JAPAN'S PATENTS, 2010 TO NOVEMBER 2014	185

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR LUNG CANCER, 2013-2019 (\$ MILLIONS)	8
FIGURE 1 CANCER RESEARCH FUNDING, 2012 (DOLLARS PER LIFE COST)	18
FIGURE 2 FEDERAL FUNDING BY CANCER SITE, 2012 (\$ MILLIONS)	18
FIGURE 3 FIVE-YEAR SURVIVAL RATES BY YEAR OF DIAGNOSIS (%)	19
FIGURE 4 MARKET SHARE OF KEY COMPANIES IN THE LUNG CANCER DIAGNOSTICS MARKET, 2014 (%)	24
FIGURE 5 DRUG DISCOVERY AND DEVELOPMENT TIMELINE	27
FIGURE 6 MUTUAL RECOGNITION PROCEDURE	30
FIGURE 7 DECENTRALIZED PROCEDURE	31
FIGURE 8 DRUG APPROVAL PROCESS IN INDIA	32
FIGURE 9 DRUG APPROVAL PROCESS IN CHINA	34
FIGURE 10 PROCEDURE FOR CLINICAL STUDIES	35
FIGURE 11 FINAL APPROVAL FOR DRUG REGISTRATION	36
FIGURE 12 PENETRANCE BREAKDOWN OF NEXT-GENERATION SEQUENCING TESTS, 2013 (%)	44
FIGURE 13 BREAKDOWN OF GENETIC TESTS MARKET, 2013 (%)	52
FIGURE 14 PREVALENCE OF LUNG CANCER BY TYPE, 2014 (%)	95
FIGURE 15 BREAKDOWN OF LUNG CANCER DIAGNOSIS BY STAGE, 2004-2010 (%)	96
FIGURE 16 NUMBER OF CANCER CASES IN THE U.S. BY TYPE, 2014 (NUMBER OF CASES)	98
FIGURE 17 ADVANTAGES AND DISADVANTAGES OF PARTICLE THERAPY	102
FIGURE 18 GLOBAL MARKET SHARE FOR LUNG CANCER SURGERY BY TYPE, 2014 (%)	104
FIGURE 19 TOP STRATEGIC ACTIVITIES OF KEY COMPANIES, 2011-NOVEMBER 2014 (NUMBER)	109
FIGURE 20 NUMBER OF PATENTS BY REGION, 2011 TO NOVEMBER 2014 (NUMBER)	176